- Home
- CGTX vs DXR Comparison
CGTX vs DXR Comparison
Compare CGTX & DXR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CGTX
- DXR
- Stock Information
- Founded
- CGTX 2007
- DXR 1970
- Country
- CGTX United States
- DXR United States
- Employees
- CGTX N/A
- DXR N/A
- Industry
- CGTX Biotechnology: Pharmaceutical Preparations
- DXR Medical/Dental Instruments
- Sector
- CGTX Health Care
- DXR Health Care
- Exchange
- CGTX Nasdaq
- DXR Nasdaq
- Market Cap
- CGTX 53.4M
- DXR 46.9M
- IPO Year
- CGTX 2021
- DXR N/A
- Fundamental
- Price
- CGTX $1.61
- DXR $11.43
- Analyst Decision
- CGTX Strong Buy
- DXR Strong Buy
- Analyst Count
- CGTX 3
- DXR 1
- Target Price
- CGTX $2.83
- DXR $25.00
- AVG Volume (30 Days)
- CGTX 8.1M
- DXR 7.4K
- Earning Date
- CGTX 11-12-2025
- DXR 01-01-0001
- Dividend Yield
- CGTX N/A
- DXR N/A
- EPS Growth
- CGTX N/A
- DXR 3.46
- EPS
- CGTX N/A
- DXR 0.36
- Revenue
- CGTX N/A
- DXR $66,306.00
- Revenue This Year
- CGTX N/A
- DXR N/A
- Revenue Next Year
- CGTX N/A
- DXR N/A
- P/E Ratio
- CGTX N/A
- DXR $32.28
- Revenue Growth
- CGTX N/A
- DXR N/A
- 52 Week Low
- CGTX $0.22
- DXR $6.55
- 52 Week High
- CGTX $3.83
- DXR $11.70
- Technical
- Relative Strength Index (RSI)
- CGTX 42.22
- DXR 52.63
- Support Level
- CGTX $1.43
- DXR N/A
- Resistance Level
- CGTX $2.60
- DXR $11.70
- Average True Range (ATR)
- CGTX 0.32
- DXR 0.51
- MACD
- CGTX -0.17
- DXR -0.42
- Stochastic Oscillator
- CGTX 10.81
- DXR 97.72
About CGTX Cognition Therapeutics Inc.
Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of, small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its product candidate CT1812, is an orally delivered, small-molecule antagonist designed to penetrate the blood-brain barrier and bind selectively to the S2R complex.
About DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.